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Abstract   
CD4 count and viral load determine the progression of HIV infection. HIV actively infects and destroys CD4 cells. 
High viral load results in higher transmission risk and is also a sign of more severe disease. Measurements of CD4 
counts can be used as an indirect means of estimating HIV viral l oad and as such determine disease progression 
and/or therapeutic outcome of antiretroviral therapy. Pharmaceutical care (PC) has been shown to improve the 
outcome of drug therapy in many disease conditions. HIV/AIDS is one of the disease conditions that are fraught with 
many problems that can benefit from this new emphasis of pharmacy practice also known as ‘pharmacists care’. This 
study  is  designed  to  evaluate  the  impact  of  pharmaceutical  care  activities  on  the  CD4 cell  counts  of  HIV/AIDS 
patients  receiving  antiretroviral  drugs.  The  components  of  the  American  society  of  health-system  pharmacists 
(ASHP) guidelines on ‘standardized method for pharmaceutical care’ was used as a data collection instrument to 
evaluate, document and intervene and re-evaluate the antiretroviral therapy of about  one thousand four hundred 
and seventy three (1,473) patients. The results showed that that 55.2% of the patients recorded significant increases 
in their CD4 cells count, 14.1% of them maintained their pre - intervention CD4 cells count while 10.3% of them 
recorded decreases in their CD4 cell count. However, in 20.4% of the patients the CD4 cell counts could not be 
determined.  The  study  showed  that  pharmacists’  interventions  in  antiretroviral  drug  therapy  through 
Pharmaceutical care can significantly improve the CD4 cells counts of patients receiving antiretroviral drugs hence 
therapeutic outcome of antiretroviral drug therapy. 
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1. Introduction 
Pharmaceutical care (PC) has been defined as the responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improves or maintains a patient’s quality of life (Hepler & Strand, 1990) as 
modified by (FIP, 1998).  The concept of pharmaceutical care is about pharmacists taking more responsibility 
for the outcome of drug therapy. It affects the way the pharmacist thinks and acts in relation to patients and 
has become a dominant aspiration of pharmacy practice worldwide in the past decade and aims to improve 
the  following  patient  outcomes  -  clinical  outcome,  humanistic  outcome  and  economic  outcome  (Oparah, 
2004). HIV/AIDS on the other hand is possibly the biggest challenge facing the healthcare system today. It is 
a condition that occurs when the HIV organism (a retrovirus) weakens the human immune system. Infection 
with the virus is a dynamic process characterized by vigorous viral replication, CD4 lymphocyte depletion 
and profound immune deficiency. 
The  concept  and  philosophy  of  pharmaceutical  care  has  been  adopted  and  implemented  in  many 
developed countries for many years now. It has achieved great successes in the care of patients in the US, UK 
and other developed countries of the world as patients in these places now get better care from Pharmacists 
who alongside the patients and healthcare managers are delighted about the initiative (Erah & Nwazuoke, 
2002). 
Antiretroviral drug therapy (ART) has faced serious challenges despite much progress and many patients 
still do not benefit from it due to viral resistance, adverse effects of chronic therapy , lack of adherence to 
complex regimens, unavailability of current agents in the developing countries (where the pandemic has its 
greatest impact). The consequences of these have been devastating to the patients, healthcare system and 
many countries.  Controlling the disease will involve ensuring that the patients receiving treatment get the 
maximum benefits of drug therapy. Thus the management of HIV/AIDS infection is one situation that has 
brought to the front burner the issue of establishing pharmaceutical care in healthcare systems [world over] 
(Obodozie, 2006). Hence the role of the Pharmacist in healthcare through the concept of pharmaceutical care 
has become imperative in the global struggle to save humanity from extinction due to HIV/AIDS. 
CD4  is  molecule  (receptor)  on  the  surfaces  of  cells  of  the  immune  system  (including  monocytes, 
macrophages, glial cells and T-cells lymphocytes also called CD4 cells or helper T-cells or T-cells) onto which 
the HIV surface glycoprotein binds. CD4 count and viral load determine the progression of HIV infection. HIV 
actively infects and destroys key cells of the immune system specifically CD-4 cells/ lymphocytes which 
reside mainly in the lymph nodes as well as other tissues of the body. These CD-4 cells are responsible for a International Journal of Development and Sustainability                                                                  Vol.1 No.3 (2012): 1187-1198 
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number of functions including regulation of host’s cell mediated immunity. Viral load is the amount of HIV in 
the blood and is measured by the HIV ribonucleic acid polymerase chain reaction test (HIV - RNA PCR). The 
viral load is very high immediately after primary HIV infection but starts decreasing with development of 
cellular immune response to the infection. Therefore it falls when the body develops antibodies and rises 
again after a period as the CD4 count drops. High viral load results in higher transmission risk and is also a 
sign of more severe disease. 
The normal CD4 count in a healthy adult us between 600 and 1500 cells/mm3 of blood. When the CD4 
count of an adult fall below 200  cells/mm3, the  risk of opportunistic and serious infection is very high 
(Sokomba and Gyang, 2006). 
 
2. Method 
The same method described in (Nwaozuzu et al., 2013) was also used in this study. This is part 2 of 4 from 
this study. The patients classified as ‘improved CD4 counts’ are those whose CD4 counts increased by 50 cells 
/ mm3 or more while those classified as ‘decreased CD4 count’ are those whose CD4 counts decreased by as 
much as 1 cell/mm3 of blood. Those whose CD4 counts did not decrease or increase by up to 50 cells/mm3 of 
blood were classified as having ‘stable CD4 counts’. Those who didn’t do their CD4 count test were classified 
as ‘indeterminate’. 
Before the study, an application for ethical approval of the study was sent to the management of the 
medical centre used for the study and the approval was granted. The components of the American society of 
health-system pharmacists (ASHP) guidelines on ‘standardized method for pharmaceutical care’ was used as 
a data collection instrument to evaluate, document and intervene in the antiretroviral therapy of about  one 
thousand four hundred and seventy three (1,473) patients. 
Data was collected from the patients’ prescription sheets, laboratory report forms, care/ART cards, and 
other  relevant  forms  in their  treatment  folders. Other  relevant  information  was  also  obtained  from  the 
patients through oral interview. The data collected at this stage formed the base-line/ pre - intervention data 
for the study. 
After documentation of these base-line data, pharmaceutical care interventions was implemented where 
necessary and this included 
1.  Patient education using a validated educational material applied uniformly to all the patients in the 
study. 
2.  Healthcare personnel education, counseling and discussions.  
3.  Recommendations for changes of drugs/regimens change of drug dose interval, duration or dosage 
form,  addition  of  more  drugs,  treatment  of  untreated  conditions,  implementation  of  non-drug 
therapy, patient referral.  
4.  Ensuring that patients do their laboratory tests.  
5.  Monitoring the laboratory test results and carrying out interventions where necessary.  International Journal of Development and Sustainability                                                                  Vol.1 No.3 (2012): 1187-1198 
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6.  Giving  patients  access  to  pharmacists  any  time  they  needed  it  i.e.  maintaining  constant 
communication between the patients and the pharmacists. 
Then a repetition of the data collection and documentation above was done nine (9) months after the 
implementation of the pharmaceutical care interventions mentioned above. This data represents the post - 
intervention data. The two data sets (baseline / pre-intervention & post-intervention data) were then be 
collated, analyzed and compared to see if the interventions resulted in any significant differences in the 
occurrence of drug therapy problems. 
Appropriate  statistical  analysis  was  also  applied  to  the  data  using  Microsoft  Excel  and  SPSS  tools. 
Inclusion and exclusion criteria used for the study were; 
1.  New patients were excluded from the study since they will have had no previous encounter with the 
system and so no existing data on them.  
2.  Patients selected were those who have received treatment, drugs and counseling from the hospital 
for at least nine (9) months (i.e. who have visited the hospital for at least three (3) times). 
3.  Both adults and children as well as males and females were involved in the study.  
4.  Patients whose medications will last for less than three (3) months will be excluded from the study. 
This is to give the interventions enough time to make impacts and produce the possible results and to 
ensure uniformity of treatment duration and contact with the pharmacist in all the participating 
patients. 
 
3. Results 
The results showed that that 55.2% of the patients recorded significant increases in their CD4 cells count, 
14.1% of them maintained their pre - intervention CD4 cells count while 10.3% of them recorded decreases 
in their CD4 cell count. However, in 20.4% of the patients the CD4 cell counts could not be determined. These 
results and other information from the study are shown in the tables below; 
 
Table 1. Age distribution  
Age Range 
Number of Patients   
Difference 
(A – B) 
 
% of total =  A 
or 
B/T x 100 
Pre - intervention 
evaluation (A)  
(% of total)   
Post - intervention 
evaluation (B)  
(% of total) 
2 yrs – 15 yrs  146  146  0  10 
15 yrs above  1327  1327  0  90 
Total (T)  1473  1473  0  100 
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Table 1 shows that 90% of patients involved in the study were adults (18years and above) while 10% of 
the patients were children (2yrs – 15yrs). 
 
  Table 2. Sex (gender) distribution 
 
 
 
 
 
 
 
 
 
  
 
 
Table  2  shows  that  most  of  the  patients  in  the  study  were  females  (65%)  while  the  male  patients 
accounted for 35% of the study population. 
 
Table 3. Distribution of CD4 cell count measurement  
VARIABLE  N0 OF PATIENTS  % OF TOTAL N0 OF PATIENTS 
EVALUATED 
Increased CD4 Count  813  55.2 
Stable CD4 Count  207  14.1 
Decreased CD4 Count  152  10.3 
Indeterminate  301  20.4 
Total  1473  100 
 
Table 3 shows that 55.2% of the patients recorded increases in their CD4 cells count, 14.1% of them 
maintained their pre - intervention CD4 cells count while 10.3% of them recorded decreases in their CD4 cell 
count. However, in 20.4% of the patients the CD4 cell counts could not be determined. 
 
4. Statistical analysis 
Hypothesis 
H0:  Pharmaceutical care interventions do not improve the therapeutic outcome (CD4 count) of antiretroviral 
drug therapy. 
Ha:  Pharmaceutical care interventions improve the therapeutic outcome (CD4 count) of antiretroviral drug 
therapy. 
sex 
Number of Patients 
 
Difference 
(A - B) 
 
% of total = A/T  
or  
B/T x 100 
Pre - intervention 
evaluation (A) 
(% of total) 
Post - intervention 
evaluation (B) 
(% of total)  
Male  513  513  0  35 
Female  960  960  0  65 
Total (T)  1473  1473  0  100 
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Here we use table 3 shown below for statistical analysis using the Pearson’s chi square (goodness of fit) 
test  to validate the result of the foregoing study. 
  
VARRIABLE  N0 OF PATIENTS  % OF TOTAL 
Increased CD4 count  813  55.2 
Stable CD4 count  207  14.1 
Decreased CD4 count  152  10.3 
Indeterminate  301  20.4 
Total  1473  100 
 
Here the expected frequency (Fe) is 50/50 because the chance probability is half (1/2) since we are 
looking at two groups of patients in the table. These are those who gave good CD4 count results (i.e. those 
with increased CD4 count (813) and those with stable CD4 count (207) as against those who gave bad CD4 
count results (those with decreased CD4 count (152). This table above is adjusted thus, 
  
VARRIABLE  NO OF PATIENTS  % OF TOTAL 
Good CD4 Result  1020  95 
Bad CD4 Result  152  5 
Total  1172  100 
 
 
As such, 
       
          
  
 
where   Fo = Observe frequency 
      Fe = Expected frequency 
Thus, 
       
            
  
 
           
  
                                
Now, degree of freedom (Df)          = (R – 1) (C – 1) 
                              = (2 – 1) (2 – 1)  
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                               = 1  
Then from Chi-square table,  
Df 1 at 95% confidence level = 3.84  
Thus, we now have  
  X2 cal = 19,026 and  
  X2 tab = 3.84 
Therefore based on our decision rule, we reject Ho and accept Ha since X2 cal > X2 tab and conclude that 
Pharmaceutical care interventions improve the therapeutic outcome of antiretroviral drug therapy. 
 
5. Discussion 
CD4 Cells are a type of white blood cells that fights infections. They are also called T-helper cells. They are 
made in the spleen, lymph nodes and thymus gland, which are part of the infection-fighting system. CD4 cells 
move throughout the body, helping it to identify and destroy germs such as bacteria and viruses (Johnson, 
2012). CD4 counts measures the number of CD4 cells in a sample of blood drawn by a needle from a vein in 
the arm. Along with other tests, the CD4 count helps tell how strong the immune system is, indicates the 
stage of your HIV disease, guides treatment and predicts how HIV infection/ disease may progress. Keeping 
the CD4 count high can reduce complications of HIV disease and prolong the patient’s life. 
The normal CD4 count of a healthy individual is between 500 and 1500 cells per cubic milliliter of blood. 
However the test does not always correspond with how well a patient is feeling. Some people can have high 
CD4 counts and do poorly while others can have low CD4 counts and have few complications. 
Antiretroviral medications are usually started when the CD4 counts is less than 200 cells/mm3 of blood. 
The fore – going study showed a positive impact of pharmaceutical care interventions on the CD4 counts 
(therapeutic outcome) in 95% of the patients whose CD4 counts were obtained. Only 5% of these patients 
experienced a decrease in their CD4 counts. These decreases were mainly due to ill – health of the patients 
and poor adherence to their medications. The Pearson chi  - square analysis / test of goodness fit of the 
results showed high levels of significance of this positive impact at p value of 0.5. The lack of CD4 count 
results for some patients were due to many factors including ill health of some patients (which made them 
unable to keep their laboratory appointments), lack of transport money to the hospital (many of them come 
from long distances to avoid their friends and relatives knowing they are infected with HIV so as to avoid 
being stigmatized), inability to sneak out of their offices to keep their laboratory appointments (since they 
don’t want their office colleagues to know about their infection so  as to avoid stigmatization), frequent 
breakdown of the CD4 machine in the hospital and lack of seriousness of some patients with laboratory 
investigations amongst other reasons. These factors need to be addressed in the interest of the patients’ International Journal of Development and Sustainability                                                                  Vol.1 No.3 (2012): 1187-1198 
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safety and the monitoring of their drug therapy to ensure optimal treatments and outcomes especially since 
CD4  count  is  the  most  affordable  and  readily  available  means  of  measuring  therapeutic  outcome  of 
antiretroviral  therapy  in  developing  countries  like  Nigeria.  The  other  laboratory  investigations  involved 
these patients’ treatment also suffered the same fate of neglect. 
These observations together with the results of this study further underscore the need and relevance of 
pharmaceutical care and the imperative of its total implementation in hospital pharmacy practice (and in 
other areas of pharmacy practice too), not only in the care of HIV patients but also in the care all classes of 
patients. 
 
6. Conclusion 
The study showed that pharmacists’ interventions in antiretroviral drug therapy through Pharmaceutical 
care  can  significantly  improve  the  CD4  cell  counts  of  patients  receiving  antiretroviral  drugs  hence  the 
therapeutic outcome of antiretroviral drug therapy. 
 
7. Recommendations 
  The need for initial and regular laboratory investigations need to be more emphasized and enforced 
before patients commence or continue their treatment. 
  The role of the pharmacist in patient counseling, drug therapy monitoring and prevention/control of 
potential  DTPs  should  be  given  more  recognition  and  encouragement.  Also  specialist  training  of 
pharmacists in these areas should be embarked on. 
  To be able to achieve the laudable goals of healthcare, adequate manpower should be made available. As 
such  governments  should  make  effort  to  train  and  employ  more  healthcare  workers  especially 
pharmacists whose numbers in hospitals are too small compared to the number of patients that need 
their attention. Pharmaceutical is both capital and manpower intensive. 
  Again, efforts should be made to equip our hospitals with more current facilities to enhance the quality of 
care in our hospitals. 
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Appendix A. Data collection form  
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